Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA

Van Rensburg, Ilana C. ; Wagman, Chandre ; Stanley, Kim ; Beltran, Caroline ; Ronacher, Katharina ; Walzl, Gerhard ; Loxton, Andre G. (2016-09)

CITATION: Van Rensburg, I. C., et al. 2016. Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA. Oncotarget, doi:10.18632/oncotarget.12184

The original publication is available at http://www.impactjournals.com/oncotarget

Publication of this article was funded by the Stellenbosch University Open Access Fund.

Article

ENGLISH ABSTRACT: Activated B-cells increase T-cell behaviour during autoimmune disease and other infections by means of cytokine production and antigen-presentation. Functional studies in experimental autoimmune encephalomyelitis (EAE) indicate that B-cell deficiencies, and a lack of IL10 and IL35 leads to a poor prognosis. We hypothesised that B-cells play a role during tuberculosis. We evaluated B-cell mRNA expression using real-time PCR from healthy community controls, individuals with other lung diseases and newly diagnosed untreated pulmonary TB patients at three different time points (diagnosis, month 2 and 6 of treatment). We show that FASLG, IL5RA, CD38 and IL4 expression was lower in B-cells from TB cases compared to healthy controls. The changes in expression levels of CD38 may be due to a reduced activation of B-cells from TB cases at diagnosis. By month 2 of treatment, there was a significant increase in the expression of APRIL and IL5RA in TB cases. Furthermore, after 6 months of treatment, APRIL, FASLG, IL5RA and CD19 were upregulated in B-cells from TB cases. The increase in the expression of APRIL and CD19 suggests that there may be restored activation of B-cells following anti-TB treatment. The upregulation of FASLG and IL5RA indicates that B-cells expressing regulatory genes may play an important role in the protective immunity against M.tb infection. Our results show that increased activation of B-cells is present following successful TB treatment, and that the expression of FASLG and IL5RA could potentially be utilised as a signature to monitor treatment response.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/99777
This item appears in the following collections: